KarMMa-3 — Idecabtagene Vicleucel Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma (KarMMa-3)
Phase 3 · 2023 · Multiple Myeloma
Design
Randomized trial of idecabtagene vicleucel versus standard regimens selected by the investigator.
Population
Relapsed and refractory multiple myeloma after 2-4 prior regimens, refractory to the last regimen.
Primary Endpoint
progression-free survival (PFS)
Key Result
PFS 13.3 vs 4.4 months (HR 0.49) with ide-cel versus standard regimens.
Guideline Impact
NCCN-listed idecabtagene vicleucel for relapsed/refractory multiple myeloma after prior therapy